about
Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series.Incidentally detected increased FDG uptake in bowel and its correlation with hystopathological data: our experience in a case series study.PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.FDG PET/CT for bone and soft-tissue biopsy.Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.(11)C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion.Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients.The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.11C-meta-hydroxyephedrine: a promising PET radiopharmaceutical for imaging the sympathetic nervous system.11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications.68Ga-DOTA-peptides in the diagnosis of NET.The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.Nuclear medicine in urological cancers: what is new?Imaging biomarkers in prostate cancer: role of PET/CT and MRI.PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer.Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).Imaging for Prostate Cancer Recurrence.Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review.Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies.Rapidly changing landscape of PET/CT imaging in prostate cancer.Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis.11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.PET Tracers Beyond FDG in Prostate Cancer.Molecular Imaging and Precision Medicine in Prostate Cancer.The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection.Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography.Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
P50
Q30444028-71F4C921-DF8B-41D5-8519-DCA73287C41BQ30831523-D53A98A6-B386-45A4-A5D1-6483F5A6A580Q31003607-506DB3E0-3A61-458C-89EF-3B6A363A30CBQ31108842-01B5FDF4-435F-4AB4-BE03-3FF0CEF7571EQ33275556-1990A3B4-59A7-4F6D-A8E6-EA053DCC17E9Q34451031-4F1181DF-344C-4B4F-8C0A-9CF587E60D79Q34479713-C46F7CCE-2CB9-4039-AEA9-C6460C1CE14FQ34507817-F0F2FE2D-29C6-4462-B4DA-E7B86ADA7D14Q35879087-6AC89512-9A1E-4246-A767-FCF0FFBA7283Q36673633-CC8B4BC7-1180-4423-97DF-2824307882E9Q37173356-AB4D2B6B-3A6B-48DC-A0DA-950FA1694391Q37249774-DC368121-8543-4341-954D-5F499E010770Q37560522-A4D4F766-B664-418D-AF7E-1B8C3F2DF255Q38204578-BF19DDD1-4F5B-44F7-BC3A-20B6BF4F47F7Q38226841-98E5E889-0C4E-458F-8B76-193407370A92Q38229217-1EE7628E-C217-4F1A-8AF3-27DEE2467E35Q38230179-9858A67A-5E7D-4592-9E43-4BAD40EBE29DQ38230239-76F03BF4-8CC2-4F2A-9391-0BB94FA10F71Q38268168-B8EE9AEB-A425-4E20-8053-C4BB27D02031Q38321182-940FE3FA-4317-4DED-B21E-E4A138220A0EQ38589076-1FB777C9-1BED-4E10-814A-DD98B5BBEEE7Q38609472-A25932DB-34A8-4325-B04D-93F988952DD1Q38655167-30515045-538F-4077-8272-49636999E255Q38667997-EA16642D-4A92-4307-9E31-4C59FEE8D502Q38706310-E551958F-C249-4F21-91D5-499F52F789B1Q38762963-BD36948E-52E4-4CB5-8D4F-802F48FD9895Q38832649-ABDA2AF1-1D50-4FEC-9A9C-FC8ACB8DED48Q38870163-E5897AEA-D38D-4CE6-A27C-A9D5226D36DFQ38911001-DB43EEC6-6750-4EF7-A0C3-977ECC686590Q38927370-1E3E22B6-F2FA-4F99-899A-C048C2EE4323Q38970106-00217AD5-5925-4E66-BA0D-F51EC2C4DF79Q38970109-C44C1C72-15ED-4247-8C70-0924B9250118Q38970117-A5A65EE6-F30C-4B7E-9FA4-70C0324EDFFEQ39003086-74C6D9EB-4E92-4901-BE1C-564F60714837Q39013373-94622823-1A2A-4859-9169-1F4EBB96D5ACQ39023651-09660BC0-88A5-4987-836E-2BF234BD2CFCQ39114508-5580368B-2B5E-4FA1-B59C-ABEC6267EE87Q39166080-FF6B872D-959A-4C19-BB63-D98FB2FF1C7CQ39258574-57F6EB32-A234-46FE-9597-BBA49F693299Q39293042-207BA9F2-B587-499F-ACB5-A8E2C06F5067
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Stefano Fanti
@ast
Stefano Fanti
@en
Stefano Fanti
@es
Stefano Fanti
@nl
type
label
Stefano Fanti
@ast
Stefano Fanti
@en
Stefano Fanti
@es
Stefano Fanti
@nl
altLabel
STEFANO FANTI
@en
prefLabel
Stefano Fanti
@ast
Stefano Fanti
@en
Stefano Fanti
@es
Stefano Fanti
@nl
P106
P1153
7004207003
P21
P31
P496
0000-0003-1486-2624